D-420720, a novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: Structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition

Drug Development Research

Volumn 69, Issue 8, 2008, Pages 514-519

  Tsai, Henry J ^a,b,c   Chou, Shan Yen ^a   Chuang, Shih Hsien ^a   Chen, Chien Cheng ^a   Hsu, Feng Lin ^d  

^a DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Inhibitor; Sulfonamide

Indexed keywords

D 420720; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STRUCTURE ACTIVITY RELATION;

EID: 58449107784     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20278     Document Type: Article

References (28)

1. Chiravuri M, Schmitz T, Yardley K, Underwood R, Dayal Y, Huber BT. 1999. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol 163:3092-3099.
2. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB. 2003. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100:6825-6830.
3. Deacon CF, Hughes TE, Holst JJ. 1998. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769.
4. de Heer J, Holst JJ. 2007. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 56:438-443.
5. de Meester I, Korom S, Van Damme J, Scharpé S. 1999. CD26, let it cut or cut it down. Immunol Today 20:367-375.
6. Demuth HU, Heins J. 1995. The catalytic mechanism of dipeptidyl peptidase IV. In: Fleischer B, editor: Dipeptidyl peptidase IV (CD26) in metabolism and the immune response. Austin, TX: RG Landes. p 1-35.
7. Demuth HU, McIntosh CH, Pederson RA. 2005. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33-44.
8. Drucker DJ. 2001. Minireview: the glucagon-like peptides. Endocrinology 142:521-527.
9. Holst JJ, Deacon CF. 1998. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670.
10. Holst JJ, Deacon CF. 2004. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 4:589-596.
11. Kojima K, Mihara R, Sakai T, Togari A, Matsui T, Shinpo K, Fujita K, Fukasawa K, Harada M, Nagatsu T. 1987. Serum activities of dipeptidyl- aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients. Biochem Med Metab Biol 37:35-41.
12. Komatsu M, Urade M, Yamaoka M, Fukasawa K, Harada M. 1987. Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells. J Natl Cancer Inst 78:863-868.
13. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT, Thornberry NA. 2003. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 371:525-532.
14. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. 2000. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97:6874-6879.
15. Meier JJ, Nauck MA. 2004. The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Invest Drugs 5:402-410.
16. Mentlein R. 1999. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
17. Oefner C, D'Arcy A, Mac Sweeney A, Pierau S, Gardiner R, Dale GE. 2003. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S) -pyrrolidine. Acta Crystallogr D Biol Crystallogr 59(Pt 7):1206-1212.
18. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258.
19. Perrella FW. 1988. EZ-FIT: a practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers. Anal Biochem 174:437-447.
20. Polgár L. 2002. The prolyl oligopeptidase family. Cell Mol Life Sci 59:349-362.
21. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750.
22. Rosenblum JS, Kozarich JW. 2003. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496-504.
23. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. 1993. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase iv enzymatic activity. Proc Natl Acad Sci USA 90: 4586-4590.
24. Underwood R, Chiravuri M, Lee H, Schmitz T, Kabcenell AK, Yardley K, Huber BT. 1999. Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 274:34053-34058.
25. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 2003. 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789.
26. Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE. 2002. 1-[2-[(5-Cyanopyridin-2-yl)amino] ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 45:2362-2365.
27. Von Bonin A, Hühn J, Fleischer B. 1998. Dipeptidyl-peptidase IV/ CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol Rev 161:43-53.
28. Weber AE. 2004. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med Chem 47:4135-4141.